Trade United Therapeutics Corp - UTHR CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.53 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023512% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.00129% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 0.1 | ||||||||
| Currency | USD | ||||||||
| Margin | 50.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 367.06 |
| Open | 367.99 |
| 1-Year Change | 72.05% |
| Day's Range | 355.7 - 367.99 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Feb 21, 2025 | 360.92 | -4.03 | -1.10% | 364.95 | 368.95 | 355.62 |
| Feb 20, 2025 | 367.06 | -8.16 | -2.17% | 375.22 | 378.15 | 362.32 |
| Feb 19, 2025 | 380.70 | 7.93 | 2.13% | 372.77 | 383.17 | 371.95 |
| Feb 18, 2025 | 372.30 | 2.35 | 0.64% | 369.95 | 373.95 | 365.92 |
| Feb 14, 2025 | 369.70 | 0.36 | 0.10% | 369.34 | 370.41 | 363.69 |
| Feb 13, 2025 | 370.33 | 5.38 | 1.47% | 364.95 | 372.29 | 364.95 |
| Feb 12, 2025 | 370.70 | 20.74 | 5.93% | 349.96 | 370.70 | 349.96 |
| Feb 11, 2025 | 353.02 | 7.06 | 2.04% | 345.96 | 362.59 | 345.96 |
| Feb 10, 2025 | 345.59 | -4.36 | -1.25% | 349.95 | 350.95 | 345.11 |
| Feb 7, 2025 | 347.64 | -6.66 | -1.88% | 354.30 | 355.94 | 344.74 |
| Feb 6, 2025 | 353.33 | 0.05 | 0.01% | 353.28 | 356.45 | 350.41 |
| Feb 5, 2025 | 354.14 | 6.18 | 1.78% | 347.96 | 358.23 | 347.96 |
| Feb 4, 2025 | 352.67 | 2.20 | 0.63% | 350.47 | 355.56 | 348.06 |
| Feb 3, 2025 | 354.53 | 6.40 | 1.84% | 348.13 | 358.06 | 344.95 |
| Jan 31, 2025 | 350.51 | -2.76 | -0.78% | 353.27 | 356.73 | 349.95 |
| Jan 30, 2025 | 352.22 | -16.74 | -4.54% | 368.96 | 369.77 | 349.35 |
| Jan 29, 2025 | 372.48 | -0.47 | -0.13% | 372.95 | 376.31 | 369.13 |
| Jan 28, 2025 | 370.29 | 0.34 | 0.09% | 369.95 | 382.40 | 367.96 |
| Jan 27, 2025 | 369.58 | 0.63 | 0.17% | 368.95 | 374.98 | 368.23 |
| Jan 24, 2025 | 370.65 | -1.25 | -0.34% | 371.90 | 375.62 | 365.67 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 20
- 100
- 500
- 1000
- 10000
United Therapeutics Company profile
About United Therapeutics Corporation
United Therapeutics Corporation is a pharmaceutical company. The Company markets and sells four commercial therapies in the United States to treat ulmonary arterial hypertension (PAH): Tyvaso (treprostinil) Inhalation Solution (Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso has also been approved to treat pulmonary hypertension associated with interstitial lung disease. It also markets and sells an oncology product, Unituxin (dinutuximab) Injection (Unituxin), which is approved for the treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin (Remunity). It also includes technologies designed supply of transplantable organs and tissues and improves outcomes for transplant recipients through regenerative medicine, three-dimensional (3-D) organ bioprinting, xenotransplantation and ex-vivo lung perfusion.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, United Therapeutics Corporation revenues increased 14% to $1.69B. Net income decreased 8% to $475.8M. Revenues reflect Tyvaso segment increase of 26% to $607.5M, Unituxin segment increase of 65% to $202.3M, United States segment increase of 11% to $1.56B, Rest-of-World segment increase of 70% to $121.3M. Net income was offset by IPR&D asset impairment charges increase from $0K to $113.4M (expense).
Equity composition
Common Stock $.01 Par, 06/11, 245M auth., 60,817,983 issd., less 2,503,657 shs. in Treas. @ $70.1M. Insiders control 1.10%. IPO: 6/17/99, 4,500,000 @ $12 by Deutsche Banc Alex. Brown. 09/09, 2-for-1 stock split.
| Industry: | Biotechnology & Medical Research (NEC) |
1000 Spring St
SILVER SPRING
MARYLAND 20910
US
News
Microsoft Stock Price Forecast for 2025 and beyond: Third party price target
We assess the likely level of the Microsoft stock price in 5 years, and possible drivers behind the stock’s past performance. Read on...
18:29, 7 February 2025
Ripple XRP price prediction: Third-party price target
Discover the ripple (XRP) price predictions for 2025 and beyond, with analyst price targets and CFDs trading strategies on Capital.com
15:29, 6 February 2025
Apple (AAPL) stock price forecast: third-party price target
We looked at the forecasts for Apple stock in 10 years to see where the price would likely be at that point and the challenges the company could face. Read more.
11:22, 6 February 2025
FARTCOIN price prediction: Third-party price target
Read our FARTCOIN price prediction for 2025 and beyond, with insights from third-party analysts and market experts
10:18, 29 January 2025
MELANIA coin ($MELANIA) price prediction: Third party price target
Read our MELANIA crypto price prediction for 2025 and beyond, with insights from third-party analysts and market experts.
11:33, 22 January 2025
TRUMP coin ($TRUMP) price prediction: third-party price target
Read our TRUMP crypto price prediction for 2025 and beyond, with insights from third-party analysts and market experts
10:52, 22 January 2025
Ethereum price prediction: Third party data round up
What is the outlook for ETH as a long-term investment?
16:37, 7 January 2025People also watch
Still looking for a broker you can trust?
Join the 690,000+ traders worldwide that chose to trade with Capital.com